

PubMed

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: <https://www.coronavirus.gov>.Get the latest research from NIH: <https://www.nih.gov/coronavirus>.

Full text links



Format: Abstract

Consult Pharm. 2007 Sep;22(9):754-62.

The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.

Miller LJ¹.

Author information

Abstract

OBJECTIVE: To review the literature for double-blind, placebo-controlled trials that examined the efficacy of cognitive enhancers in the psychopathology of Alzheimer's disease.

DATA SOURCES: Literature searches were conducted using MEDLINE and EMBASE databases and clinicaltrials.gov.

STUDY SELECTION: Overall, 55 articles were reviewed for inclusion. Several open-label studies and case reports were found on this topic, but only those involving both tacrine and use of the Neuropsychiatric Inventory were included. Regarding other drugs, only double-blind, placebo-controlled trials were selected for inclusion.

DATA SYNTHESIS: Limited data suggest that the anticholinesterase inhibitors and **memantine** offer an alternative or adjunct to the antipsychotics for the treatment of moderate-to-severe behaviors. The author reviewed the literature for pharmacological management of behavioral and psychological symptoms of dementia (**BPSD**) using these cognitive enhancers.

CONCLUSION: The majority of patients with Alzheimer's disease will experience behavioral disturbances during the course of their disease. Atypical antipsychotics are used routinely in these situations to treat the psychotic features and agitation. However, atypicals now carry a "black box" warning issued by the Food and Drug Administration on the basis of evidence that their use in geriatric patients with dementia-related psychosis may put patients at increased risk of mortality as a result of cardiovascular or infectious events. An alternative to the atypicals may be the acetylcholinesterase inhibitors and **memantine**, which have been shown to stabilize cognitive as well as behavioral issues in patients, utilizing the "gold standard" for behavior, the Neuropsychiatric

Inventory. Efficacy varies among agents, with the greatest positive effects seen with donepezil, which also has the greatest number of studies. Drug benefits were harder to demonstrate for mild-to-moderate **BPSD** compared with moderate-to-severe symptoms.

Comment in

Psychotherapeutic medications and dementia. [Consult Pharm. 2008]

PMID: 18198970 DOI: [10.4140/tcp.n.2007.754](https://doi.org/10.4140/tcp.n.2007.754)

[Indexed for MEDLINE]

Publication type, MeSH terms, Substances

LinkOut - more resources